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were discounted at 3.5%. The base case analysis used a conservative estimate of 80 kg  
for the patient. Uncertainty around the cost effectiveness estimates was explored using          
one-way and probabilistic sensitivity analysis. RESULTS: Inﬂiximab verses ciclosporin   
resulted in an ICER of £19,290 while inﬂiximab therapy dominated standard care and 
surgery treatment options. Changing the utility estimates, medium term ciclosporin 
colectomy probability, and long term treatment effect results in the ICER values being 
above the cost effectiveness threshold of £30,000 per QALY. CONCLUSIONS: 
 Inﬂiximab can be considered as a cost effective treatment compared to standard            
care in patients with severely active ulcerative colitis (UC) hospitalised with an acute 
exacerbation in Scotland.
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OBJECTIVES: To estimate resource utilization and direct medical cost of chronic 
hepatitis C (CHC) from a Thai payer perspective. METHODS: Medical records of 
CHC patients diagnosed during 2003–2006 at 5 major tertiary-care hospitals in 
Thailand were retrospectively reviewed. Data on CHC-related resource use were col-
lected from diagnosis date to the end of 2007 or the last follow-up date or death date, 
depending on which date came ﬁrst. Using micro-costing method, resource utilization 
categorized as laboratory tests, outpatient visits (OPD), inpatient admissions (IPD), 
procedures and medications were measured for 6 health states of CHC, i.e. CHC, 
compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocellular carcinoma 
(HCC), liver transplantation at year 1 (LT1), and subsequent years post-transplantation 
(LT2). Costs were estimated using reference prices published by Ministry of Public 
Health and were valued in year 2008 Thai Baht (35 Baht  1 USD). RESULTS: A 
total of 542 patients were identiﬁed with 1578 person-years of follow-up time. OPD 
rate was highest in HCC (7 visits/patient/year). IPD rates increased by 289% from 
CC to DC and 1377% from CC to HCC. Mean lengths of stay per admission were 
9 days in DC and 6 days in HCC. Usage rates of medications for liver complications 
were also increased in DC and HCC. Average annual treatment costs per patient were: 
CHC 243,292 Baht (US$6,951); CC 251,148 Baht (US$7,176); DC 154,686 Baht 
(US$4,420); HCC 171,975 Baht (US$4,914); LT-1, 608,771 Baht (US$17,393) and 
LT2 100,818 Baht (US$2,881). CONCLUSIONS: Resource utilization rates in 
CHC patients increase as the disease progresses. Although inpatient bed charges are 
relatively low and no doctor fee paid for outpatient visits in public hospitals, consump-
tion of these health care resources could have been avoided. Interventions which 
prevent or delay liver disease progressions will profoundly reduce economic burden 
of CHC.
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OBJECTIVES: Constipation is a frequent and possibly debilitating adverse event of 
analgesic treatment with opioids. A new drug combining the opioid oxycodone and 
the opioid antagonist naloxone provides equivalent analgesia to oxycodone alone with 
signiﬁcant improvement in bowel function, as demonstrated in a 12-week randomized 
controlled trial in moderate/severe non-cancer pain (OXN3001). This analysis assessed 
the cost-utility of oxycodone/naloxone vs. oxycodone in Belgium and The Nether-
lands. METHODS: A decision model was developed in MS Excel™. In this model, 
costs (a, Societal perspective) and effects (QALYs) of both strategies were calculated 
over a 3 (base case) to 12-month horizon (no discounting). The proportion of patients 
experiencing opioid-induced constipation (OIC) was derived from the OXN3001 trial. 
Medical resource use for OIC prevention, treatment and complications was collected 
using a Delphi panel including 24 Belgian and Dutch GPs. National tariffs were 
applied to obtain corresponding costs. Utility scores were derived from the SF-36 
questionnaire collected during the OXN3001 trial. Deterministic and probabilistic 
sensitivity analyses were performed. RESULTS: At 3 months, oxycodone/naloxone 
was dominant over oxycodone in The Netherlands, while the incremental cost-
 effectiveness ratio (ICER) was a16,389a/QALY in Belgium (incremental drug cost: 
The Netherlands a115, Belgium 153a; OIC-related savings The Netherlands 136a, 
Belgium a110; QALYs gained: both countries 0.0026). At 12 months, the ICER was 
a12,786/QALY in The Netherlands and a25,421/QALY in Belgium. The proportion 
of patients experiencing at least 1 OIC episode during a 4-week analgesic treatment 
was the most sensitive parameter. A Monte Carlo analysis showed that, assuming a 
willingness to pay threshold of a20,000/QALY (The Netherlands) and a30,000/QALY 
(Belgium), oxydone/naloxone was cost-effective in 58% (The Netherlands) and 63% 
(Belgium) of the 1000 simulations (3-month horizon). CONCLUSIONS: Analgesia 
with oxycodone/naloxone is cost-effective (Belgium) or even dominant (The Netherlands) 
at three months and remains cost-effective up to one year.
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OBJECTIVES: To estimate the resource use and associated cost of treating opioid-
induced constipation (OIC) episodes in cancer patients in Sweden where laxatives 
within current SPC-text have failed. METHODS: Nurses in 3 hospices and 10 home 
care centers across Sweden with experience in caring for cancer patients on opioid 
therapy were selected to participate in an interview series. An interview protocol was 
developed in consultation with an expert. The nurses reported on the frequency of 
OIC episodes, treatment practices and resource use related to constipation. The cost 
components included personnel costs (based on time spent on constipation-related 
tasks), transportation costs (for home care visits) and resource costs. The cost per hour 
for personnel was based on the average salary levels of applicable medical personnel 
in Sweden and overhead cost. The average cost per constipation episode was estimated 
and used to project direct health care cost of OIC in Sweden. RESULTS: The nurses 
reported that on average 24% of patients in home care and 45% of patients in hospices 
had a constipation episode every second week or more often with laxatives in labeled 
doses. The nurses estimated the length of the constipation episode to be between 2–5 
days. Three steps were identiﬁed in the treatment process—increase in dosage of laxa-
tives (100%), provision of suppositories and enemas (40%) and manual disimpaction 
or bowel investigation/contrast X-ray (3% of cases). Nurses spent on average 3.5 
hours ranging across 2 additional visits for treating each episode of OIC. The average 
cost per episode of OIC was estimated to SEK 1700. Direct health care costs of OIC 
in cancer patients who have failed laxatives within current SPC-text, were estimated 
to SEK 40 million per year in Sweden. CONCLUSIONS: Opioid-induced constipation 
in cancer patients in Sweden is associated with signiﬁcant resource use and costs.
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OBJECTIVES: To assess the extent and main drivers of health care resource consump-
tion in patients admitted with non-variceal upper gastrointestinal bleeding (NVUGIB). 
METHODS: This observational, retrospective cohort study (NCT00797641; 
ENERGiB) was conducted in several European countries (Belgium, Greece, Italy, 
Norway, Portugal, Spain and Turkey). Eligible patients were those consecutively 
admitted to hospital (1 October–30 November 2008) who underwent endoscopy for 
overt NVUGIB (haematemesis, melaena or haematochezia, with other clinical/labora-
tory evidence of acute upper gastrointestinal blood loss). Management of patients 
proceeded according to routine care at each centre. During a 30-day follow-up period, 
data on various clinical outcomes were collected from patient medical records. The 
present analysis reports differences between countries in consumption of health care 
resources. RESULTS: A total of 2661 patients (65% men; mean age 67.7 years) were 
enrolled. The mean number of days of hospitalisation (standard deviation [SD]) was 
8.9 (5.9) days. A wide inter-country variation was observed, ranging from 7.4 (4.9) 
days in Turkey to 10.8 (7.5) days in Belgium. Empirical treatment for NVUGIB was 
administered pre-endoscopy in 68.9% of patients (range 35.1% [Belgium] to 88.7% 
[Turkey]), most frequently proton pump inhibitors (PPIs) (66.0% of patients, ranging 
from 32.8% [Belgium] to 87.7% [Turkey]). Therapeutic procedures were performed 
during endoscopy in 35.8% of patients (range 24.9% [Greece] to 40.6% [Belgium]). 
Most commonly performed related procedures were transfusions (any intravenous 
ﬂuid; 84.6% of patients, range 74.0% [Belgium] to 92.3% [Portugal]) and additional 
endoscopies (28.7%, range 12.6% [Turkey] to 53.6% [Belgium]). Treatment for 
NVUGIB was administered post-endoscopy in 93.2% of patients, most commonly 
PPIs (92.6%); a narrow inter-country range was observed. CONCLUSIONS: Manage-
ment of NVUGIB is associated with substantial consumption of health care resources 
in European countries. There is wide variation across Europe; generally, the highest 
rates of resource utilisation are observed in Belgium and the lowest in Turkey.
GASTROINTESTINAL DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To assess the effect of subcutaneous Methylnaltrexone on generic 
Health Related Quality of Life using the EQ-5D index scores in patients on opioid 
therapy for chronic non-malignant pain with opioid-induced constipation. METHODS: 
In this study, 469 subjects were randomized to either methylnaltrexone daily (QD), 
every other day (QOD) dosing or placebo for 4 weeks. Eligibility criteria included an 
